pembrolizumab
merck
['congrat', 'melanoma', 'pembro']
practice changing results presented by at #esmo2022 presidential session. indisputable efs benefit of neoadjuvant vs adjuvant pembro (hr 0.58, p 0.004) in high risk resectable melanoma! congrats &amp; 
#Melanoma medical oncologist and #immunotherapy & drug development investigator at @MDAndersonNews. Co-Director of the #BrainMets Clinic. Views are my own.